Company Fundamentals - The company has reported losses for five consecutive years (2021-2025), with an expected net profit loss of 100 to 140 million yuan in 2025 [1] - The asset-liability ratio has risen to 68.67% as of the end of September 2025, with accounts receivable amounting to 1.016 billion yuan, accounting for 51% of current assets, indicating high repayment risk [1] - High R&D investment has increased by 50.9% year-on-year in the first three quarters of 2025, along with depreciation of production capacity, further eroding profits and raising concerns about the company's ongoing viability [1] Regulatory Situation - In February 2026, the company received a regulatory warning from the Shanghai Stock Exchange for disseminating inaccurate information regarding its CPI aerospace applications and microfluidic biochip businesses [2] - A previous response led to a temporary stock price surge, but subsequent clarifications revealed that aerospace orders accounted for less than 0.1% of revenue, and biochip business revenue was only 107,900 USD, unrelated to brain-computer interfaces, raising doubts about business authenticity [2] Project Progress - The company plans to raise 1.5 billion yuan through a private placement to expand production of glass-based MiniLED modules, aiming to increase capacity from 60,000 pieces per year to 6.05 million pieces per year [3] - However, from April to October 2025, the capacity utilization rate for this business was only 30%, generating approximately 12 million yuan in revenue, leading to concerns about over-expansion and potential idle capacity [3] Financial and Technical Aspects - As of February 11, 2026, the stock price had dropped by 12.52% from the high on February 4, with short-term moving averages showing a bearish trend and a weakening MACD indicator [4] - Concurrently, there has been an increase in net capital outflow, reflecting heightened risk-averse sentiment among investors [4]